Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 167, Issue 2, Pages 417-423
Publisher
Wiley
Online
2012-03-14
DOI
10.1111/j.1365-2133.2012.10940.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
- (2011) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: A case series
- (2011) Ting-Shun WANG et al. JOURNAL OF DERMATOLOGY
- Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
- (2010) D. Salmon-Ceron et al. ANNALS OF THE RHEUMATIC DISEASES
- Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies
- (2010) J. Santos-Juanes et al. BRITISH JOURNAL OF DERMATOLOGY
- Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
- (2010) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges
- (2010) D Pathirana et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
- (2009) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry
- (2009) F. Tubach et al. ARTHRITIS AND RHEUMATISM
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
- (2009) C.H. Smith et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab
- (2009) Antonio Giovanni Richetta et al. Dermatologic Therapy
- Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation
- (2009) Misha Rosenbach et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- From biologic to biologic to biologic: Lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis
- (2008) Leona Yip et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
- (2008) J. Schmitt et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started